Display options
Cite
Moriyama J, Oshima Y, Nanami T, et al. Prognostic impact of CEA/CA19-9 at the time of recurrence in patients with gastric cancer. Surg Today. 2021;51(10):1638-1648doi: 10.1007/s00595-021-02248-y.
Moriyama, J., Oshima, Y., Nanami, T., Suzuki, T., Yajima, S., Shiratori, F., Funahashi, K., & Shimada, H. (2021). Prognostic impact of CEA/CA19-9 at the time of recurrence in patients with gastric cancer. Surgery today, 51(10), 1638-1648. https://doi.org/10.1007/s00595-021-02248-y
Moriyama, Jin, et al. "Prognostic impact of CEA/CA19-9 at the time of recurrence in patients with gastric cancer." Surgery today vol. 51,10 (2021): 1638-1648. doi: https://doi.org/10.1007/s00595-021-02248-y
Moriyama J, Oshima Y, Nanami T, Suzuki T, Yajima S, Shiratori F, Funahashi K, Shimada H. Prognostic impact of CEA/CA19-9 at the time of recurrence in patients with gastric cancer. Surg Today. 2021 Oct;51(10):1638-1648. doi: 10.1007/s00595-021-02248-y. Epub 2021 Mar 07. PMID: 33682011.
Copy Download .nbib Format: NLM
Share it on

Surg Today. 2021 Oct;51(10):1638-1648. doi: 10.1007/s00595-021-02248-y. Epub 2021 Mar 07.

Prognostic impact of CEA/CA19-9 at the time of recurrence in patients with gastric cancer.

Surgery today

Jin Moriyama, Yoko Oshima, Tatsuki Nanami, Takashi Suzuki, Satoshi Yajima, Fumiaki Shiratori, Kimihiko Funahashi, Hideaki Shimada

Affiliations

  1. Department of Clinical Oncology, Toho University Graduate School of Medicine, Ota-ku, Tokyo, Japan.
  2. Department of Surgery, Toho University School of Medicine, Ota-ku, Tokyo, Japan.
  3. Department of Clinical Oncology, Toho University Graduate School of Medicine, Ota-ku, Tokyo, Japan. [email protected].
  4. Department of Surgery, Toho University School of Medicine, Ota-ku, Tokyo, Japan. [email protected].
  5. Department of Gastroenterological Surgery and Clinical Oncology, Graduate School of Medicine, Toho University, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan. [email protected].

PMID: 33682011 DOI: 10.1007/s00595-021-02248-y

Abstract

PURPOSE: We evaluated the clinical impact of the carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) values at the time of recurrence in gastric cancer patients.

METHODS: Among 790 patients with R0 resected gastric cancer without neoadjuvant therapy between 2004 and 2017, 89 recurrence cases were retrospectively evaluated. The clinical impact of CEA and CA19-9 values on recurrence sites and post-recurrent prognosis were evaluated using univariate and multivariate analyses.

RESULTS: The positive rates of CEA and CA19-9 at recurrence were significantly higher than the preoperative positive rates (CEA, 56% vs 24%; CA19-9, 37% vs 15%). Although CA19-9-positive patients at recurrence exhibited a poor survival, the difference was not significant. The positive rates of CEA at liver or lymph node recurrence were significantly higher than the preoperative positive rates. The positive rate of CA19-9 at peritoneal recurrence was significantly higher than the preoperative positive rate. CA19-9-positive patients at recurrence exhibited worse prognosis than CA19-9-negative patients, although the difference was not significant. At lymph node recurrence, CA19-9-positive patients exhibited a significantly worse survival than CA19-9-negative patients.

CONCLUSION: In recurrent gastric cancer, the positive status of CA19-9 at recurrence might have a negative prognostic impact after recurrence; particularly, in patients with lymph node recurrence.

© 2021. Springer Nature Singapore Pte Ltd.

Keywords: CA19-9; CEA; Gastric cancer; Prognosis; Recurrence

References

  1. Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388:2654–64. - PubMed
  2. Oshima Y, Suzuki T, Yajima S, Nanami T, Shiratori F, Funahashi K, et al. Serum p53 antibody: useful for detecting gastric cancer but not for predicting prognosis after surgery. Surg Today. 2020;50:1402–8. - PubMed
  3. Ito M, Oshima Y, Yajima S, Suzuki T, Nanami T, Shiratori F, et al. Diagnostic impact of high serum midkine level in patients with gastric cancer. Ann Gastroenterol Surg. 2019;3:195–201. - PubMed
  4. Hoshino I, Nabeya Y, Takiguchi N, Gunji H, Ishige F, Iwatate Y, et al. Prognostic impact of p53 and/or NY-ESO-1 autoantibody induction in patients with gastroenterological cancers. Ann Gastroenterol Surg. 2020;4:275–82. - PubMed
  5. Shimada H, Noie T, Ohashi M, Oba K, Takahashi Y. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the task force of the Japanese gastric cancer association. Gastric Cancer. 2014;17:26–33. - PubMed
  6. Suenaga Y, Kanda M, Ito S, Mochizuki Y, Teramoto H, Ishigure K, et al. Prognostic significance of perioperative tumor marker levels in stage II/III gastric cancer. World J Gastrointest Oncol. 2019;11:17–27. - PubMed
  7. Uda H, Kanda M, Tanaka C, Kobayashi D, Inaoka K, Tanaka Y, et al. Perioperative serum carcinoembryonic antigen levels predict recurrence and survival of patients with pathological T2–4 gastric cancer treated with curative gastrectomy. Dig Surg. 2018;35:55–63. - PubMed
  8. Wang W, Chen XL, Zhao SY, Xu YH, Zhang WH, Liu K, et al. Prognostic significance of preoperative serum CA125, CA19-9 and CEA in gastric carcinoma. Oncotarget. 2016;7:35423–36. - PubMed
  9. Liu X, Qiu H, Liu J, Chen S, Xu D, Li W, et al. Combined preoperative concentrations of CEA, CA 19-9, and 72-4 for predicting outcomes in patients with gastric cancer after curative resection. Oncotarget. 2016;7:35446–53. - PubMed
  10. Takahashi Y, Takeuchi T, Sakamoto J, Touge T, Mai M, Ohkura H, et al. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. Gastric Cancer. 2003;6:142–5. - PubMed
  11. Komatsu S, Ichikawa D, Nishimura Y, Kubota T, Okamoto K, Shiozaki A, et al. Better outcomes by monitoring tumour dynamics using sensitive tumour markers in patients with recurrent gastric cancer. Anticancer Res. 2013;33:1621–7. - PubMed
  12. Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48:452–8. - PubMed
  13. Feng F, Tian Y, Xu G, Liu Z, Liu S, Zheng G, et al. Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer. BMC Cancer. 2017;17:737. - PubMed
  14. Lee EC, Yang JY, Lee KG, Oh SY, Suh YS, Kong SH, et al. The value of postoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the early detection of gastric cancer recurrence after curative resection. J Gastric Cancer. 2014;14:221–8. - PubMed
  15. Sawayama H, Iwatsuki M, Kuroda D, Toihata T, Uchihara T, Koga Y, et al. The association of the lymph node ratio and serum carbohydrate antigen 19-9 with early recurrence after curative gastrectomy for gastric cancer. Surg Today. 2018;48:994–1003. - PubMed
  16. Wada N, Kurokawa Y, Miyazaki Y, Makino T, Takahashi T, Yamasaki M, et al. The characteristics of the serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer cases. Surg Today. 2017;47:227–32. - PubMed
  17. Wu F, Shi C, Wu R, Huang Z, Chen Q. Peritoneal recurrence in gastric cancer following curative resection can be predicted by postoperative but not preoperative biomarkers: a single-institution study of 320 cases. Oncotarget. 2017;8:78120–32. - PubMed
  18. Zhou YC, Zhao HJ, Shen LZ. Preoperative serum CEA and CA19-9 in gastric cancer–a single tertiary hospital study of 1075 cases. Asian Pac J Cancer Prev. 2015;16:2685–91. - PubMed
  19. Ushigome M, Shimada H, Miura Y, Yoshida K, Kaneko T, Koda T, et al. Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA. Int J Clin Oncol. 2020;25:622–32. - PubMed
  20. Song YX, Huang XZ, Gao P, Sun JX, Chen XW, Yang YC, et al. Clinicopathologic and prognostic value of serum carbohydrate antigen 19-9 in gastric cancer: a meta-analysis. Dis Markers. 2015;2015:549843. - PubMed
  21. Kotzev AI, Draganov PV. Carbohydrate antigen 19-9, carcinoembryonic antigen, and carbohydrate antigen 72-4 in gastric cancer: is the old band still playing? Gastrointest Tumors. 2018;5:1–13. - PubMed
  22. Bebnowska D, Grywalska E, Niedzwiedzka-Rystwej P, Sosnowska-Pasiarska B, Smok-Kalwat J, Pasiarski M, et al. CAR-T cell therapy-an overview of targets in gastric cancer. J Clin Med. 2020;9:1894. - PubMed

Publication Types